贝尔加普通过抑制铁灭菌来改善纤维化
Li Li1, Wenqian Cai1, Hao Zhang1
1Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Phytotherapy research : PTR
|January 7, 2025
概括
伯加是一种天然化合物,通过抑制亡,这是病进展的关键过程,在治疗纤维化方面表现有前途. 这项研究揭示了bergapten的存在.
科学领域:
- 科和药理学 科和药理学
- 细胞生物学和病理学
背景情况:
- 纤维化是末期病的主要原因,治疗选择有限.
- 铁,一种依赖于铁的细胞死亡途径,在纤维化中起着关键作用.
- 柏加的治疗潜力,一种天然氨酸,在纤维化中仍然在很大程度上未被探索.
研究的目的:
- 研究柏加对纤维化的治疗作用.
- 阐明贝加的作用的基本机制,重点关注铁灭.
- 评估贝加作为纤维化的潜在治疗方法.
主要方法:
- 纤维化的体内和体外模型,包括单边尿路阻塞 (UUO) 和TGF-β1/RSL3诱导的损伤.
- 网络药理学分析,以预测贝加的目标.
- 用RNA测序 (RNA-Seq) 来探索分子机制.
- 评估纤维化标志物 (纤维素,α-SMA) 和铁亡指标 (GPX4).
主要成果:
- 伯加在体内和体外模型中都表现出显著的抗纤维菌作用.
- 在UUO小鼠中,Bergapten治疗降低了关键纤维化标志物 (纤维肌菌素,α-SMA).
- 伯加有效地抑制了TGF-β1诱导的纤维化和RSL3诱导的化在管状上皮细胞中.
- 该机制涉及PI3K酸化的抑制,导致GPX4表达的恢复和ferroptosis抑制.
结论:
- 柏加对纤维化具有显著的脏保护作用.
- 伯加通过调节PI3K/GPX4通路来抑制铁亡,缓解纤维化.
- 伯加代表了对纤维化和其他与死相关的疾病的有前途的治疗剂.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:11Renal Failure: Dose Adjustments
62
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
01:25Antihypertensive Drugs: Direct Renin Inhibitors
484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K